Vycor Medical Q2 Revenue Falls 16% as Going Concern Warning Looms
VYCO has more than doubled off its 52-week low of $0.032 on light trading volume (0.1× avg).
Summary
Vycor Medical reported Q2 2026 revenue of $418,264, down 16% year-over-year, driven by a 17% decline in its core VBAS division, mostly from international markets. Gross profit fell 19% to $327,225, though margins held at 82%. Non-GAAP operating profit dropped to $22,952 from $85,712 a year earlier. The company also highlighted three new peer-reviewed VBAS studies, bringing the total to 53, which could support future adoption. This follows the 10-Q filed earlier today disclosing a going concern warning, material weakness in internal controls, and only $158,907 in cash with a $300,000 debt maturity looming. The revenue decline and weak cash position reinforce the financial distress already flagged in the filing. Watch for any financing or restructuring announcements given the near-term debt maturity.
At the time of this announcement, VYCO was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.03 to $0.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: EQS.